What if you invested $1000 in BIIB on Jan 1, 2020?
Explore hypothetical investment results for stocks, ETFs, and more. See real historical data and share your discoveries.
Historical Annual Returns
Over the past 20 years, Biogen Inc. has delivered an average annual return of 9.4%. The stock peaked in 2013 with a massive +86.4% gain, while investors faced a downturn in 2024 (-42.9%). Overall, the stock finished in the green 11 times out of 20 years.
Avg Return
+9.4%
Win Rate
55%
11W - 9L
Best
+86.4%
2013
Worst
-42.9%
2024
Performance Consistency
About Biogen Inc.
Visit Website ↗Biogen Inc. is an American multinational biotechnology company specializing in the discovery, development, and delivery of innovative therapies for people living with serious neurological and neurodegenerative diseases. The company focuses on conditions such as multiple sclerosis (MS), Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA).
Key Business Segments
Multiple Sclerosis
Develops and commercializes therapies for multiple sclerosis.
Alzheimer's Disease and Dementia
Focuses on research and development of treatments for Alzheimer's disease and related dementias.
Spinal Muscular Atrophy (SMA)
Develops and commercializes therapies for spinal muscular atrophy.
Neuroscience
Includes research and development in areas such as Parkinson's disease, ALS, and other neurological disorders.
Key Innovations
- ✓Pioneered the use of recombinant DNA technology in the biotechnology industry.
- ✓Developed Spinraza, the first approved treatment for spinal muscular atrophy (SMA).
Historical Milestones
Biogen is founded in Geneva, Switzerland, by a group of prominent biologists.
Biogen launches its Initial Public Offering (IPO).
Biogen merges with IDEC Pharmaceuticals to form Biogen Idec.
The company reverts to its original name, Biogen Inc.
Biogen acquires Reata Pharmaceuticals, expanding its portfolio in rare neurological diseases.